Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

50%

4 of 8 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

Phase 4

1(20.0%)

5Total

N/A(2)

Phase 2(1)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00893815Completed

Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients

Role: collaborator

NCT00622843Phase 3Completed

Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

Role: collaborator

NCT05677282Phase 4Recruiting

Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct

Role: collaborator

NCT00804713Not ApplicableCompleted

Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits

Role: collaborator

NCT00996970Completed

Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons

Role: collaborator

NCT00889577Completed

Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons

Role: collaborator

NCT00631566Not ApplicableCompleted

Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

Role: collaborator

NCT00859677Completed

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection

Role: collaborator

NCT03455309Phase 2Completed

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

Role: collaborator

All 9 trials loaded